Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
- Resource Type
- Article
- Source
- In
Blood 15 November 2008 112(10):3959-3964 - Subject
- Language
- ISSN
- 0006-4971